ICML 2017 - 14th International Conference on Malignant Lymphoma
Jun 14 - Jun 17, 2017 | LuganoSwitzerland
LARVOL is not affiliated with 14th International Conference on Malignant Lymphoma and all trademarks, logos, and brand names are property of their respective owners
Showing 78 abstracts linked to Trials
Biomarker analysis of patients with follicular lymphoma treated with ibrutinib in the phase 2 DAWN study
GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19-TARGETED THERAPY CTL019 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)—AN INTERIM ANALYSIS
PROGNOSTIC VALUE OF PET-CT AFTER FIRST-LINE IMMUNOCHEMOTHERAPY FOR FOLLICULAR LYMPHOMA IN THE PHASE III GALLIUM STUDY
FDG-PET as a Biomarker of Response in DLBCL: the HOVON 84 Study Experience
CELL OF ORIGIN COMBINED WITH CNS INTERNATIONAL PROGNOSTIC INDEX IMPROVES IDENTIFICATION OF DLBCL PATIENTS WITH HIGH CNS RELAPSE RISK AFTER INITIAL IMMUNOCHEMOTHERAPY
A NEW BCL-2 INHIBITOR (S55746/BCL201) AS MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMA: PRELIMINARY RESULTS OF THE FIRST-IN-HUMAN STUDY
Phase I Study of IPH4102, Anti-KIR3DL2 Mab, in Relapsed/Refractory Cutaneous T-Cell Lymphomas (CTCL): Dose-escalation Safety, Biomarker and Clinical Activity Results
FIRST CLINICAL RESULTS OF ADCT-402, A NOVEL PYRROLOBENZODIAZEPINE-BASED ANTIBODY DRUG CONJUGATE (ADC), IN RELAPSED/REFRACTORY B-CELL LINEAGE NHL
A PHASE II LYSA STUDY OF OBINUTUZUMAB COMBINED WITH LENALIDOMIDE FOR RELAPSED OR REFRACTORY FOLLICULAR B-CELL LYMPHOMA
PHASE IB STUDY OF CC-122 IN COMBINATION WITH OBINUTUZUMAB (GA101): RELAPSED OR REFRACTORY (R/R) PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMAS (NHL)
Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE-170 phase 2 trial
BLOCKADE OF THE PD-1 CHECKPOINT WITH ANTI–PD-L1 ANTIBODY AVELUMAB IS SUFFICIENT FOR CLINICAL ACTIVITY IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (CHL)
CLINICAL OUTCOMES AND MOLECULAR CHARACTERIZATION FROM a PHASE II STUDY OF COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
IBRUTINIB IN RELAPSE OR REFRACTORY PRIMARY CNS AND VITREO-RETINAL LYMPHOMA. RESULTS OF THE PRIMARY END-POINT OF THE ILOC PHASE II STUDY FROM THE LYSA AND THE FRENCH LOC NETWORK.
BRENTUXIMAB VEDOTIN CONSOLIDATION TO REDUCE RADIATION USE IN PATIENTS WITH LIMITED STAGE NON-BULKY HODGKIN LYMPHOMA: AN UPDATE FROM a PHASE 2 CLINICAL TRIAL